Journal Mobile Options
Table of Contents
Vol. 16, No. 3, 2003
Issue release date: July 2003
Dement Geriatr Cogn Disord 2003;16:136–144

Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s Disease

Sun Y.-X. · Minthon L. · Wallmark A. · Warkentin S. · Blennow K. · Janciauskiene S.
aDepartment of Medicine, Malmö University Hospital, bDepartment of Psychiatry, Neuropsychiatric Clinic, Malmö University Hospital, Malmö, cDepartment of Clinical Neuroscience, Unit of Neurochemistry, UniversityofGöteborg, Göteborg,Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


It has been suggested that a number of molecules associated with inflammation are involved in the pathogenesis of Alzheimer’s disease (AD). We measured the levels of α1-antichymotrypsin (ACT), α1-antitrypsin (AAT), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and oxidised low-density lipoprotein (oxLDL) in matched cerebrospinal fluid (CSF) and plasma of 141 patients with probable AD. We found a significant relationship between CSF and plasma levels of ACT (r = 0.4, p < 0.001), IL-6 (r = 0.74, p < 0.001), MCP-1 (r = 0.71, p < 0.001), and a borderline relationship between CSF and plasma oxLDL (r = 0.22, p < 0.05). In addition, linear regression analysis revealed a positive correlation between levels of CSF-ACT and oxLDL (p < 0.001), but an inverse relation between levels of CSF ACT, CSF AAT and MCP-1 (p < 0.001). A significant correlation was also found between levels of CSF ACT, oxLDL and the ratio of CSF to serum albumin, which is used as a measure of the blood-brain barrier function. Our data extend previous reports regarding the inflammatory markers in the plasma and CSF of patients with AD and provide good evidence that levels of ACT, IL-6, MCP-1 and oxLDL in plasma and CSF might be candidates as biomarkers for monitoring the inflammatory process in AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Meda L, Baron P, Scarlato G: Glial activation in Alzheimer’s disease: The role of Aβ and its associated proteins. Neurobiol Aging 2001;22:885–893.
  2. Muller-Spahn F, Hock C: Risk factors and differential diagnosis of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 1999;249(suppl 3):37–42.
  3. Hutton M, Perez-Tur J, Hardy J: Genetics of Alzheimer’s disease. Essays Biochem 1998;33:117–131.
  4. Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA: Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62–73 years. Alzheimer Dis Assoc Disord 1998;12:40–44.
  5. Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, Mizusawa H: Lack of genetic associations of α1-antichymotrypsin polymorphism with Alzheimer-type neuropathological changes or sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord 1999;10:221–225.
  6. Green EK, Harris JM, Lemmon H, Lambert JC, Chartier-Harlin MC, St Clair D, Mann DM, Iwatsubo T, Lendon CL: Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology 2002;58:1566–1568.
  7. Bhojak TJ, DeKosky ST, Ganguli M, Kamboh MI: Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer’s disease. Neurosci Lett 2000;288:21–24.
  8. Infante J, Llorca J, Berciano J, Combarros O: No synergistic effect between –850 tumor necrosis factor-α promoter polymorphism and apolipoprotein E epsilon 4 allele in Alzheimer’s disease. Neurosci Lett 2002;328:71–73.
  9. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer’s disease. Neurobiol Aging 2000;21:383–421.
  10. McGeer PL, McGeer EG: Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001;22:799–809.
  11. McGeer PL, McGeer EG: The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.
  12. Dong Y, Benveniste EN: Immune function of astrocytes. Glia 2001;36:180–190.
  13. Hauss-Wegrzyniak B, Lukovic L, Bigaud M, Stoeckel ME: Brain inflammatory response induced by intracerebroventricular infusion of lipopolysaccharide: An immunohistochemical study. Brain Res 1998;794:211–224.
  14. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW: Identification of oxidized plasma proteins in Alzheimer’s disease. Biochem Biophys Res Commun 2002;293:1566–1570.

    External Resources

  15. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM: Increased plasma levels of interleukin-1, interleukin-6 and α1-antichymotrypsin in patients with Alzheimer’s disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 2000;103:97–102.
  16. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C: Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002;23:485–508.
  17. Calingasan NY, Gibson GE: Vascular endothelium is a site of free radical production and inflammation in areas of neuronal loss in thiamine-deficient brain. Ann NY Acad Sci 2000;903:353–356.
  18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  19. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  20. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid β-amyloid(1–42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673–680.
  21. Tibbling G, Link H, Ohman S: Principles of albumin and IgG analyses in neurological disorders. 1. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385–390.
  22. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C: Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 1993;33:129–133.
  23. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–245.
  24. Vanderstichele H, Blennow K, D’Heuvaert N, Buyse M, Wallin A, Andreasen N, Seubert P, Van De Voorde A, Vanmechelen E: Development of a specific diagnostic test for measurement of β-amyloid (1–42) in CSF; in Fisher A, Hanin I, Yoshida M (eds): Progress in Alzheimer’s and Parkinson’s Disease. New York, Plenum, 1998, pp 773–778.
  25. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
  26. Laurell CB: Electroimmuno assay. Scand J Clin Lab Invest 1972;124:21–37.
  27. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W: APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001;12:69–77.
  28. Steinmetz A: Phenotyping of human apolipoprotein E from whole blood plasma by immunoblotting. J Lipid Res 1987;28:1364–1370.
  29. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K: Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: Establishment of reference values. Clin Chem 2001;47:1776–1781.
  30. Rosenfeld ME: Cellular mechanisms in the development of atherosclerosis. Diabetes Res Clin Pract 1996;30(suppl):1–11.
  31. De Simoni MG, Sironi M, De Luigi A, Manfridi A, Mantovani A, Ghezzi P: Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J Exp Med 1990;171:1773–1778.
  32. De Simoni MG, Del Bo R, De Luigi A, Simard S, Forloni G: Central endotoxin induces different patterns of interleukin (IL)-1-β and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology 1995;136:897–902.
  33. Combrinck MI, Perry VH, Cunningham C: Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience 2002;112:7–11.

    External Resources

  34. Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE: Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism. Am J Pathol 2000;156:797–805.
  35. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, Bading J, Frangione B, Zlokovic BV: Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer’s amyloid-β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998;70:210–215.
  36. Mooradian AD: Effect of aging on the blood-brain barrier. Neurobiol Aging 1988;9:31–39.
  37. Ito U, Ohno K, Yamaguchi T, Takei H, Tomita H, Inaba Y: Effect of hypertension on blood-brain barrier. Change after restoration of blood flow in post-ischemic gerbil brains. An electronmicroscopic study. Stroke 1980;11:606–611.
  38. Schmidt R, Schmidt H, Fazekas F: Vascular risk factors in dementia. J Neurol 2000;247:81–87.
  39. Strazielle N, Ghersi-Egea JF, Ghiso J, Dehouck MP, Frangione B, Patlak C, Fenstermacher J, Gorevic P: In vitro evidence that β-amyloid peptide 1–40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol 2000;59:29–38.
  40. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S–629S.
  41. Santos MS, Santos DL, Palmeira CM, Seica R, Moreno AJ, Oliveira CR: Brain and liver mitochondria isolated from diabetic Goto-Kakizaki rats show different susceptibility to induced oxidative stress. Diabetes Metab Res Rev 2001;17:223–230.
  42. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U: Increased lipoprotein oxidation in Alzheimer’s disease. Free Radic Biol Med 2000;28:351–360.
  43. Keller JN, Hanni KB, Markesbery WR: Oxidized low-density lipoprotein induces neuronal death: Implications for calcium, reactive oxygen species, and caspases. J Neurochem 1999;72:2601–2609.
  44. Ma J, Yee A, Brewer HB Jr, Das S, Potter H: Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92–94.
  45. Eriksson S, Janciauskiene S, Lannfelt L: α1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl Acad Sci USA 1995;92:2313–2317.
  46. Janciauskiene S, Sun Y, Wright H: Interactions of Aβ with endogenous anti-inflammatory agents: A basis for chronic neuroinflammation in Alzheimer’s disease. Neurobiol Dis 2002;10:187–200.

    External Resources

  47. Licastro F, Masliah E, Pedrini S, Thal LJ: Blood levels of α1-antichymotrypsin and risk factors for Alzheimer’s disease: Effects of gender and apolipoprotein E genotype. Dement Geriatr Cogn Disord 2000;11:25–28.
  48. Scacchi R, Ruggeri M, Gambina G, Martini MC, Ferrari G, Corbo RM: Plasma α1-antichymotrypsin in Alzheimer’s disease; relationships with APOE genotypes. Neurobiol Aging 2001;22:413–416.
  49. Hayashi M, Luo Y, Laning J, Strieter RM, Dorf ME: Production and function of monocyte chemoattractant protein-1 and other β-chemokines in murine glial cells. J Neuroimmunol 1995;60:143–150.

    External Resources

  50. Gale LM, McColl SR: Chemokines: Extracellular messengers for all occasions? Bioessays 1999;21:17–28.
  51. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, Gladue R, Rollins B: In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 1997;62:577–580.
  52. Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M: Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 1999;14:376–382.
  53. Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, Shioi T, Okada M, Iwasaki A, Nishio R, Matsushima K, Sasayama S: Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997;29:419–423.
  54. Rollins BJ: Monocyte chemoattractant protein-1: A potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996;2:198–204.
  55. Inadera H, Egashira K, Takemoto M, Ouchi Y, Matsushima K: Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res 1999;19:1179–1182.

    External Resources

  56. Taekema-Roelvink ME, Kooten C, Kooij SV, Heemskerk E, Daha MR: Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. J Am Soc Nephrol 2001;12:932–940.
  57. Yamaguchi Y, Matsumura F, Liang J, Okabe K, Ohshiro H, Ishihara K, Matsuda T, Mori K, Ogawa M: Neutrophil elastase and oxygen radicals enhance monocyte chemoattractant protein-expression after ischemia/reperfusion in rat liver. Transplantation 1999;68:1459–1468.
  58. Lomas DA, Stone SR, Llewellyn-Jones C, Keogan MT, Wang ZM, Rubin H, Carrell RW, Stockley RA: The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin. J Biol Chem 1995;270:23437–23443.
  59. Micksche M, Kokron O: Serum levels of α1-antitrypsin and α2-macroglobulin in lung cancer. Osterr Kneipp Mag 1977;3:116–119.
  60. Kilpatrick L, Johnson JL, Nickbarg EB, Wang ZM, Clifford TF, Banach M, Cooperman BS, Douglas SD, Rubin H: Inhibition of human neutrophil superoxide generation by α1-antichymotrypsin. J Immunol 1991;146:2388–2393.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50